Provided by Tiger Trade Technology Pte. Ltd.

Galmed Pharmaceuticals

4.31
-0.2550-5.59%
Post-market: 4.15-0.1550-3.60%19:30 EDT
Volume:22.21K
Turnover:95.79K
Market Cap:4.48M
PE:-0.27
High:4.54
Open:4.54
Low:4.12
Close:4.56
52wk High:13.20
52wk Low:3.29
Shares:1.04M
Float Shares:1.01M
Volume Ratio:0.22
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.1401
EPS(LYR):-19.1292
ROE:-72.12%
ROA:-33.45%
PB:0.32
PE(LYR):-0.23

Loading ...

Galmed Pharmaceuticals Buys Colospan in Deal Valued up to $5.3 Million

Reuters
·
Jul 09

Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal

MT Newswires Live
·
Jun 22

BRIEF-Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd.

Reuters
·
Jun 22

Galmed restructures Colospan deal terms, swaps $2 million share payment for earnout and extra cash

Reuters
·
Jun 22

Galmed Pharmaceuticals - Increases Cash Payment by $800K, Restructures $2 Mln Earnout Starting Q3 2027

THOMSON REUTERS
·
Jun 22

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition

THOMSON REUTERS
·
Jun 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)

TIPRANKS
·
Jun 11

Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion

TIPRANKS
·
Jun 08

Galmed Pharmaceuticals - Colospan Shareholders to Receive $2.5 Mln Cash and $2 Mln in Galmed Shares at Closing

THOMSON REUTERS
·
Jun 08

Galmed Pharmaceuticals - Plans $6 Mln Investment to Launch Colospan Device in Europe During H2 2026

THOMSON REUTERS
·
Jun 08

Galmed Pharmaceuticals to Acquire Colospan to Create a Gi-Focused Platform Targeting a $6 Billion Market

THOMSON REUTERS
·
Jun 08

UK's Mhra: Resmetirom (Rezdiffra) Authorised to Treat Metabolic Dysfunction-Associated Steatohepatitis (Mash) in Adults

THOMSON REUTERS
·
Jun 03

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

TIPRANKS
·
Jun 02

Galmed, Tissue Dynamics say Aramchol combo cuts fibrosis about 4-fold in human cardiac organoid study

Reuters
·
Jun 02

Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
May 18

Galmed reports results from first-in-man PK study of Aramchol Meglumine

TIPRANKS
·
May 14

Galmed Announces Results From First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (Am); 400Mg Am Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (Aa) 300Mg

THOMSON REUTERS
·
May 14

Galmed Pharmaceuticals Partners with Tissue Dynamics on Human Cardiac Fibrosis Platform

TIPRANKS
·
May 06

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

THOMSON REUTERS
·
May 06

Galmed partners Tissue Dynamics to develop chronic cardiac fibrosis organoid platform

Reuters
·
May 06